Jingfeng Pharmaceutical(SZ:000908)2024-06-23 03:48Group 1: Company Financial Status - The company reported a revenue of 10,057.57 million yuan in Q1 2024, which does not include income from Dalian Dezhe [1][4] - The company is actively working to improve its financial situation by increasing net assets and reducing debt [2][4] Group 2: Risk Management and Response - The company is aware of the risk of delisting and is exploring various self-rescue measures to stabilize its stock price [1][2] - A special task force has been established to address current challenges and ensure normal operations [1][2] Group 3: Product and Market Development - As of December 31, 2023, the company has 48 products listed in the National Basic Medical Insurance Directory, including 19 Class A and 29 Class B products [3] - The company is negotiating with several large private medical groups to expand sales channels for its products [2][4] Group 4: Internal Management and Control - The company is enhancing budget control and internal management processes to ensure compliance and operational efficiency [2][4] - Legal measures are being taken to recover outstanding receivables, maximizing the company's financial interests [2][4] Group 5: Research and Development - The company has received production licenses for several new products and is actively pursuing clinical research for others [4] - Ongoing studies include the evaluation of new indications for existing products to participate in the national insurance directory adjustments [3][4]